Antiviral activity of a small-molecule inhibitor of filovirus infection

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 5, 2010, Pages 2152-2159

  Warren, Travis K ^a   Warfield, Kelly L ^a,b   Wells, Jay ^a   Enterlein, Sven ^a   Smith, Mark ^a   Ruthel, Gordon ^a   Yunus, Abdul S ^c   Kinch, Michael S ^c   Goldblatt, Michael ^c   Aman, M Javad ^b   Bavari, Sina ^a  

^a UNITED STATES ARMY MEDICAL RESEARCH INSTITUTE OF INFECTIOUS DISEASES   (United States)

^b Integrated BioTherapeutics Inc   (United States)

^c Functional Genetics Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTIVIRUS AGENT; ASPARTATE AMINOTRANSFERASE; CYTOKINE; FGI 103; GREEN FLUORESCENT PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DEMOCRATIC REPUBLIC CONGO; DRUG EFFICACY; EBOLA VIRUS; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY PARENCHYMA; LIVER; MARBURG VIRUS; MOLECULAR LIBRARY; MOUSE; MOUSE STRAIN; NONHUMAN; PATHOLOGY; PRIORITY JOURNAL; SINGLE DRUG DOSE; SPLEEN; SUDAN; TREATMENT DURATION; VIREMIA; VIRUS INFECTION; VIRUS LOAD; VIRUS STRAIN; WILD TYPE;

AMIDINES; ANIMALS; ANTIVIRAL AGENTS; BENZOFURANS; CERCOPITHECUS AETHIOPS; CYTOKINES; EBOLAVIRUS; FEMALE; FILOVIRIDAE; FILOVIRIDAE INFECTIONS; GREEN FLUORESCENT PROTEINS; HEMORRHAGIC FEVER, EBOLA; HEP G2 CELLS; HUMANS; KIDNEY; LIVER; MALE; MARBURG VIRUS DISEASE; MARBURGVIRUS; MICE; MICE, INBRED C57BL; MOLECULAR WEIGHT; SMALL MOLECULE LIBRARIES; VERO CELLS;

EID: 77951240331     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01315-09     Document Type: Article

References (24)

1. Aman, M. J., M. S. Kinch, K. Warfield, T. Warren, A. Yunus, S. Enterlein, E. Stavale, P. Wang, S. Chang, Q. Tang, K. Porter, M. Goldblatt, and S. Bavari. 2009. Development of a broad-spectrum antiviral with activity against Ebola virus. Antiviral Res. 83:245-251.
2. Anonymous. 2009. Ebola Reston in pigs and humans, Philippines. Wkly. Epidemiol. Rec. 84:49-50.
3. Bray, M., K. Davis, T. Geisbert, C. Schmaljohn, and J. Huggins. 1998. A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J. Infect. Dis. 178:651-661.
4. Bray, M., J. Driscoll, and J. W. Huggins. 2000. Treatment of lethal Ebola virus infection in mice with a single dose of an S-adenosyl-L-homocysteine hydrolase inhibitor. Antiviral Res. 45:135-147.
5. Bray, M., J. L. Raymond, T. Geisbert, and R. O. Baker. 2002. 3-Deazaneplanocin A induces massively increased interferon-alpha production in Ebola virus-infected mice. Antiviral Res. 55:151-159.
6. Centers for Disease Control and Prevention. 2005. Outbreak of Marburg virus hemorrhagic fever-Angola, October 1, 2004-March 29, 2005. MMWR Morb. Mortal. Wkly. Rep. 54:308-309.
7. Dolnik, O., L. Kolesnikova, and S. Becker. 2008. Filoviruses: interactions with the host cell. Cell. Mol. Life Sci. 65:756-776.
8. Emeny, J. M., and M. J. Morgan. 1979. Regulation of the interferon system: evidence that Vero cells have a genetic defect in interferon production. J. Gen. Virol. 43:247-252.
9. Gibb, T. R., M. Bray, T. W. Geisbert, K. E. Steele, W. M. Kell, K. J. Davis, and N. K. Jaax. 2001. Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J. Comp. Pathol. 125:233-242.
10. Hensley, L. E., H. A. Young, P. B. Jahrling, and T. W. Geisbert. 2002. Proinflammatory response during Ebola virus infection of primate models: possible involvement of the tumor necrosis factor receptor superfamily. Immunol. Lett. 80:169-179.
11. Kinch, M. S., A. S. Yunus, C. Lear, H. Mao, H. Chen, Z. Fesseha, G. Luo, E. A. Nelson, L. Li, Z. Huang, M. Murray, W. Y. Ellis, L. E. Hensley, J. Christopher-Hennings, G. G. Olinger, and M. Goldblatt. 2009. FGI-104: a broad-spectrum small molecule inhibitor of viral infection. Am. J. Transl. Res. 1:87-98.
12. Kortepeter, M. G., J. W. Martin, J. M. Rusnak, T. J. Cieslak, K. L. Warfield, E. L. Anderson, and M. V. Ranadive. 2008. Managing potential laboratory exposure to Ebola virus by using a patient biocontainment care unit. Emerg. Infect. Dis. 14:881-887.
13. Kuhn, J. H. 2008. Filoviruses: a compendium of 40 years of epidemiological, clinical, and laboratory studies. Springer, New York, NY.
14. Mahanty, S., M. Gupta, J. Paragas, M. Bray, R. Ahmed, and P. E. Rollin. 2003. Protection from lethal infection is determined by innate immune responses in a mouse model of Ebola virus infection. Virology 312:415-424.
15. Martin-Serrano, J., T. Zang, and P. D. Bieniasz. 2001. HIV-1 and Ebola virus encode small peptide motifs that recruit Tsg101 to sites of particle assembly to facilitate egress. Nat. Med. 7:1313-1319.
16. Normile, D. 2009. Emerging infectious diseases. Scientists puzzle over Ebola- Reston virus in pigs. Science 323:451.
17. Panchal, R. G., G. Ruthel, T. A. Kenny, G. H. Kallstrom, D. Lane, S. S. Badie, L. Li, S. Bavari, and M. J. Aman. 2003. In vivo oligomerization and raft localization of Ebola virus protein VP40 during vesicular budding. Proc. Natl. Acad. Sci. U. S. A. 100:15936-15941.
18. Silvestri, L. S., G. Ruthel, G. Kallstrom, K. L. Warfield, D. L. Swenson, T. Nelle, P. L. Iversen, S. Bavari, and M. J. Aman. 2007. Involvement of vacuolar protein sorting pathway in Ebola virus release independent of TSG101 interaction. J. Infect. Dis. 196(Suppl. 2):S264-S270.
19. Streeter, D. G., J. T. Witkowski, G. P. Khare, R. W. Sidwell, R. J. Bauer, R. K. Robins, and L. N. Simon. 1973. Mechanism of action of 1-D-ribofuranosyl-1,2,4-triazole-3-carboxamide (Virazole), a new broad-spectrum antiviral agent. Proc. Natl. Acad. Sci. U. S. A. 70:1174-1178.
20. Timen, A., M. P. Koopmans, A. C. Vossen, G. J. van Doornum, S. Gunther, F. van den Berkmortel, K. M. Verduin, S. Dittrich, P. Emmerich, A. D. Osterhaus, J. T. van Dissel, and R. A. Coutinho. 2009. Response to imported case of Marburg hemorrhagic fever, the Netherlands. Emerg. Infect. Dis. 15:1171-1175.
21. Towner, J. S., J. Paragas, J. E. Dover, M. Gupta, C. S. Goldsmith, J. W. Huggins, and S. T. Nichol. 2005. Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and highthroughput antiviral drug screening. Virology 332:20-27.
22. Urata, S., T. Noda, Y. Kawaoka, S. Morikawa, H. Yokosawa, and J. Yasuda. 2007. Interaction of Tsg101 with Marburg virus VP40 depends on the PPPY motif, but not the PT/SAP motif as in the case of Ebola virus, and Tsg101 plays a critical role in the budding of Marburg virus-like particles induced by VP40, NP, and GP. J. Virol. 81:4895-4899.
23. Warfield, K. L., D. A. Alves, S. B. Bradfute, D. K. Reed, S. VanTongeren, W. V. Kalina, G. G. Olinger, and S. Bavari. 2007. Development of a model for marburgvirus based on severe-combined immunodeficiency mice. Virol. J. 4:108.
24. Warfield, K. L., S. B. Bradfute, J. Wells, L. Lofts, M. T. Cooper, D. A. Alves, D. K. Reed, S. A. VanTongeren, C. A. Mech, and S. Bavari. 2009. Development and characterization of a mouse model for Marburg hemorrhagic fever. J. Virol. 83:6404-6415.